Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 12, Issue 3, Pages 443-450Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00660
Keywords
Hematopoetic progenitor kinase 1; HPK1; MAP4K1; cancer immunotherapy
Categories
Ask authors/readers for more resources
The study presents a novel HPK1 inhibitor which, when used in combination in a colorectal cancer model, significantly enhances the efficacy of anti-PD1 treatment.
While the discovery of immune checkpoint inhibitors has led to robust, durable responses in a range of cancers, many patients do not respond to currently available therapeutics. Therefore, an urgent need exists to identi alternative mechanisms to augment the immune-mediated clearance of tumors. Hematopoetic progenitor kinase 1 (HPK1) is a serine-threonine kinase that acts as a negative regulator of T-cell receptor (TCR) signaling, to dampen the immune response. Herein we describe the structure-based discovery of isofuranones as inhibitors of HPK1. Optimization of the chemotype led to im provements in potency, selectivity, plasma protein binding, and metabolic stability, culminating in the identification of compound 24. Oral administration of 24, in combination with an anti-PD1 antibody, demonstrated robust enhancement of anti-PD1 efficacy in a syngeneic tumor model of colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available